DIFFERENTIAL ANALYSIS OF WRN INTERACTING PARTNERS AFTER CISPLATINUM TREATMENT

顺铂治疗后 WRN 相互作用伙伴的差异分析

• 批准号: 8171393
• 负责人: Michael MacCoss
• 金额: $ 0.67万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8171393
• 关键词: Apoptosis; Cells; Cisplatin; Complex; Computer Retrieval of Information on Scientific Projects Database; DNA; Embryo; Funding; Grant; Human; Institution; Kidney; Mass Spectrum Analysis; Pharmaceutical Preparations; Proteins; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Work; chemotherapy; crosslink; protein complex; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is known that cells deficient in the Werner protein (WRN) are specifically sensitive to cisplatinum (cis-Pt), a chemotherapy drug that works by crosslinking DNA and triggering apoptosis. Our profiling analysis of cells exposed to this drug is aimed at understanding the mechanisms cells employ to resolve the resulting damage, and how WRN protein is involved in these mechanisms. In order to understand WRN involvement, we aim to analyze its associated protein complex. By using a genetically encoded TAP tag, we are enriching for the WRN and its partners from whole cell lysates in human embryonic kidney (HEK-293) cells and are proposing to analyze these complexes by profiling mass spectrometry. Our lab has previously established conditions for treating cells with these chemotherapeutic compounds, and initial experiments with cell treatment have been performed. We are currently awaiting first MS results.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 众所周知，Werner蛋白(WRN)缺陷的细胞对顺铂(cis-pt)特别敏感，顺铂是一种通过交联DNA和引发细胞凋亡的化疗药物。我们对暴露于这种药物的细胞的图谱分析旨在了解细胞用来解决由此造成的损害的机制，以及WRN蛋白是如何参与这些机制的。 为了了解WRN的参与，我们的目标是分析其相关的蛋白质复合体。通过使用基因编码的TAP标签，我们正在从人类胚胎肾脏(HEK-293)细胞的全细胞裂解物中为WRN及其合作伙伴进行丰富，并建议通过剖析质谱图来分析这些复合体。 我们的实验室以前已经建立了用这些化疗化合物治疗细胞的条件，并进行了细胞治疗的初步实验。我们目前正在等待第一个多发性硬化症结果。